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Abstract
Background—It is unclear whether aggressive phototherapy to prevent neurotoxic effects of
bilirubin benefits or harms infants with extremely low birth weight (1000 g or less).
Methods—We randomly assigned 1974 infants with extremely low birth weight at 12 to 36 hours
of age to undergo either aggressive or conservative phototherapy. The primary outcome was a
composite of death or neurodevelopmental impairment determined for 91% of the infants by
investigators who were unaware of the treatment assignments.
Results—Aggressive phototherapy, as compared with conservative phototherapy, significantly
reduced the mean peak serum bilirubin level (7.0 vs. 9.8 mg per deciliter [120 vs. 168 μmol per liter],
P<0.01) but not the rate of the primary outcome (52% vs. 55%; relative risk, 0.94; 95% confidence
interval [CI], 0.87 to 1.02; P = 0.15). Aggressive phototherapy did reduce rates of
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neurodevelopmental impairment (26%, vs. 30% for conservative phototherapy; relative risk, 0.86;
95% CI, 0.74 to 0.99). Rates of death in the aggressive-phototherapy and conservative-phototherapy
groups were 24% and 23%, respectively (relative risk, 1.05; 95% CI, 0.90 to 1.22). In preplanned
subgroup analyses, the rates of death were 13% with aggressive phototherapy and 14% with
conservative phototherapy for infants with a birth weight of 751 to 1000 g and 39% and 34%,
respectively (relative risk, 1.13; 95% CI, 0.96 to 1.34), for infants with a birth weight of 501 to 750
g.
Conclusions—Aggressive phototherapy did not significantly reduce the rate of death or
neurodevelopmental impairment. The rate of neurodevelopmental impairment alone was
significantly reduced with aggressive phototherapy. This reduction may be offset by an increase in
mortality among infants weighing 501 to 750 g at birth. (ClinicalTrials. gov number, NCT00114543.)
It is controversial whether modest elevations of total serum bilirubin (hereafter referred to
simply as “bilirubin”) cause brain damage in preterm infants.1-4 Some observational studies
of preterm infants have suggested that bilirubin levels as low as 5 mg per deciliter (86 μmol
per liter) or even lower may cause neurodevelopmental deficits.5-8 However, other
observational studies have suggested that moderately higher bilirubin levels have no neurotoxic
effects9-11 or might even benefit these infants,12 because bilirubin is an antioxidant.
Phototherapy is considered to be effective and safe in reducing bilirubin levels.13 However, it
has been studied in only one large, randomized trial involving infants treated in the 1970s.14
No neurodevelopmental benefits were identified,15 and the findings suggested the possibility
that phototherapy might increase the risk of death relative to that among controls in the same
birth-weight stratum: for birth weight below 2500 g, the relative risk was 1.32 (95% confidence
interval [CI], 0.96 to 1.82); for birth weight below 1000 g, the relative risk was 1.49 (95% CI,
0.93 to 2.40).16,17 Since that trial was reported, the levels of irradiance delivered by
phototherapy lamps have substantially increased, with uncertain effects on the risks and
benefits of phototherapy.
We conducted a multicenter, randomized trial comparing the effect of aggressive phototherapy
as compared with conservative phototherapy on the incidence of death or neurodevelopmental
impairment among infants of extremely low birth weight at 18 to 22 months after the expected
date of delivery (the corrected age).
Methods
The institutional review boards at RTI International and all 16 Neonatal Research Network
clinical centers (see the Appendix) approved the study. Written informed consent was obtained
from the parent or guardian of each participant.
Patients
Infants with a birth weight of 501 to 1000 g were eligible for enrollment between 12 and 36
hours of age. Exclusion criteria were a terminal condition (defined as a pH <6.8 or persistent
bradycardia with hypoxemia for >2 hours), previous phototherapy, a major congenital
anomaly, hydrops fetalis or severe hemolytic disease, congenital nonbacterial infection, or a
judgment that the parents would be unable or unlikely to return for assessments at 18 to 22
months.
Enrollment and Treatment
Infants were stratified on the basis of birth weight (501 to 750 g or 751 to 1000 g) and center
and were then randomly assigned to a treatment group by means of a centralized computer
system. The protocol stipulated the use of phototherapy during the first 14 days after birth. In
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both groups, phototherapy was provided for at least 24 consecutive hours after it was started
or restarted.
For infants in the aggressive-phototherapy group, phototherapy was initiated at enrollment
(when the bilirubin level was expected to be approximately 5 mg per deciliter). For infants
with a birth weight of 501 to 750 g, the aggressive phototherapy was continued or restarted
whenever the bilirubin level was found to be 5 mg per deciliter or higher. For infants with a
birth weight of 751 to 1000 g, the aggressive phototherapy was continued or restarted whenever
the bilirubin level was found to be 5 mg per deciliter or higher during the first 7 days after birth
and 7 mg per deciliter (120 μmol per liter) or higher during the next 7 days. Conservative
phototherapy was initiated, continued, or restarted whenever the bilirubin level was 8 mg per
deciliter (137 μmol per liter) or higher for infants weighing 501 to 750 g at birth and 10 mg
per deciliter (171 μmol per liter) or higher for infants weighing 751 to 1000 g at birth.
A baseline bilirubin level was measured within 4 hours before or at enrollment for the first 100
infants enrolled in each treatment group. Bilirubin was measured at least once daily for the
first 7 days after birth for all infants. During the second week after birth, bilirubin was measured
on any day on which phototherapy was administered or when phototherapy had been stopped
in the previous 24 hours or the last bilirubin measurement exceeded 5 mg per deciliter for
infants with a birth weight of 501 to 750 g or 7 mg per deciliter for infants with a birth weight
751 to 1000 g. A parent or guardian of 1101 infants consented to the collection of an additional
blood sample on day 5 of the treatment period, which was sent to Stanford University or Brown
University for assay of the serum level of unbound bilirubin according to the Arrow technique.
18 Unbound bilirubin (which accumulates when the bilirubin-binding capacity of albumin has
been exceeded) was assessed because the neurotoxic effects of bilirubin are thought to be
caused by entry of unbound bilirubin into the brain.18
On the basis of current phototherapy recommendations and practice,13 the target irradiance
level was 15 to 40 μW per square centimeter per nanometer of wavelength and was measured
by research personnel and bedside nurses. Irradiance levels were increased, within this range,
if the bilirubin level exceeded 13 mg per deciliter (222 μmol per liter) for infants with a birth
weight of 501 to 750 g and 15 mg per deciliter (256 μmol per liter) for infants with a birth
weight of 751 to 1000 g. An exchange transfusion was indicated for any infant whose bilirubin
level exceeded the threshold after 8 hours of this intensified treatment. The study was designed
as an effectiveness trial,19 and the brand and number of phototherapy lights, administration of
fluids, feedings, and other interventions were chosen at the discretion of the caregivers.
Assessments
Research nurses recorded all data using standardized definitions. Bronchopulmonary dysplasia
was identified by the administration of supplemental oxygen therapy at 36 weeks of
postmenstrual age. Outcomes at 18 to 22 months of corrected age were assessed by neurologic
examiners and neurodevelopmental testers who had been trained for reliability of assessments
during a 2-day workshop and were unaware of the treatment assignments.20
The primary outcome was death or neurodevelopmental impairment at 18 to 22 months of
corrected age. This composite outcome was selected because infants who died before 18
months of corrected age could not be classified as having neurodevelopmental impairment.
Neurodevelopmental impairment was defined as blindness (no functional vision in either eye),
severe hearing loss (hearing loss for which bilateral hearing aids were prescribed), moderate
or severe cerebral palsy, or a score below 70 on the Mental or Psychomotor Developmental
Index of the Bayley Scales of Infant Development II (on which scores can range from 50 to
150, with 150 indicating the most advanced development).21 Secondary outcomes included
each of the individual outcomes above and predefined clinical diagnoses or potential adverse
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events. Cerebral palsy was defined as a nonprogressive disorder of the central nervous system
characterized by abnormal muscle tone in at least one arm or leg and abnormal control of
movement or posture with delayed attainment of motor milestones. Infants were classified as
having moderate or severe cerebral palsy if they were able to walk only with assistive devices
or were unable to walk at all, respectively. Hearing outcomes were determined by the
neurologic examiner and reports by parents or guardians. If a hearing loss was present, more
information was collected to determine the nature of the deficit and whether hearing aids were
prescribed. In post hoc analyses, we used a definition of profound impairment that was similar
to the definition in a previous analysis by our group22: a score on the Mental or Psychomotor
Developmental Index of 50 or less or a level of 5 for gross motor function, according to the
modified criteria of Palisano et al.23 (on which the level of motor function can range from 0
to 5, with 5 indicating that movement requires assistance by an adult).
Statistical Analysis
A difference of 7 percentage points between the two treatment groups in the rate of the primary
outcome was considered clinically important. To detect this difference with an alpha value of
0.05 and a statistical power of 0.80, we planned to study 1976 infants. Intention-to-treat
analyses were performed. The denominator used to calculate the rate of each outcome was the
number of infants for whom that outcome was known. Analyses were conducted at the Neonatal
Research Network data coordinating center, at RTI International, and were adjusted for the
stratification variables (birth weight and center) with the use of robust Poisson regression
analyses to estimate the adjusted relative risk. Additional regression analyses involved
adjustment for the infants' sex, race or ethnic group, and location of birth (within or outside of
the network center). To assess whether differences between groups might be explained by
differences in rates of bronchopulmonary dysplasia between the two groups, separate
regression analyses were performed in which bronchopulmonary dysplasia was added as a
predictor variable.
Prespecified subgroup analyses were conducted for each birth-weight stratum. We included
an interaction term for birth-weight stratum with treatment group and assessed the statistical
significance of the interaction term. A two-sided P value of less than 0.05 was considered to
indicate statistical significance. Analyses did not include adjustment for multiple comparisons.
24
Our findings prompted us to perform post hoc analyses of profound impairment, as well as
Bayesian analyses25-29 of overall outcomes and outcomes according to birth-weight
stratum30 (for details, see the Supplementary Appendix, available with the full text of this
article at www.nejm.org). No other post hoc analyses were performed.
RTI International tracked hearing assessments and deaths before discharge, since data for the
primary outcome would not be available before 18 to 22 months. An independent data and
safety monitoring committee reviewed the interim results, including those concerning adverse
outcomes, four times. Pocock boundaries were used to develop stopping rules for interim safety
monitoring of death and for hearing loss. The nominal significance level was 0.05 and the
critical P value for each review was set at 0.0158.
Results
Between September 2002 and April 2005, we enrolled 1974 (69%) of 2873 eligible infants
(Fig. 1). The aggressive-phototherapy group and the conservative-phototherapy group were
generally similar, with small differences in the percentages of male infants and black infants
(Table 1).
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As expected, the two groups differed significantly in mean and peak bilirubin levels, unbound
bilirubin on day 5, and the duration of phototherapy (Table 2). The proportion of infants
receiving phototherapy and the mean bilirubin levels are shown according to day after birth
and treatment group in Fig. 1A and 1B in the Supplementary Appendix. Phototherapy was
never given to 1 of the 990 infants (<1%) in the aggressive-phototherapy group and to 215 of
the 984 infants (22%) in the conservative-phototherapy group. Among infants who did receive
phototherapy, the mean irradiance levels were 22 to 23 μW per square centimeter per nanometer
each day.
The bilirubin level in 3 infants in the aggressive-phototherapy group and 13 in the conservative-
phototherapy group exceeded the threshold, resulting in intensified phototherapy. Two infants
receiving aggressive phototherapy and 3 receiving conservative phototherapy received an
exchange transfusion; an additional infant in each group who met criteria for exchange
transfusion did not undergo the procedure, on the basis of the judgment of the attending
neonatologist.
The rates of prespecified secondary outcomes before hospital discharge are shown in Table 2.
The relative risks for bronchopulmonary dysplasia and the composite outcome of
bronchopulmonary dysplasia or death were significantly reduced with aggressive phototherapy
as compared with conservative phototherapy, but those for the other 12 predischarge outcomes
were not. The relative risks shown in Table 2 changed only minimally in analyses that involved
adjustment for race or ethnic group, sex, and location of birth of infants (data not shown).
Outcomes at 18 to 22 Months
The primary outcome of death or neurodevelopmental impairment was determined for 1804
infants (91% of the 1974 who underwent randomization); whether the infant died was known
for 1890 (96%). The proportion of infants with the primary outcome was 52% in the aggressive-
phototherapy group and 55% in the conservative-phototherapy group (relative risk, 0.94; 95%
CI, 0.87 to 1.02; P = 0.15) (Table 3). (The relative risk in analyses that were also adjusted for
race or ethnic group, sex, and location of birth was 0.96 [95% CI, 0.89 to 1.04], P = 0.33.)
Death occurred in 24% of infants in the aggressive-phototherapy group and 23% of those in
the conservative-phototherapy group (relative risk, 1.05; 95% CI, 0.90 to 1.22). The rate of
neurodevelopmental impairment was lower with aggressive phototherapy than with
conservative therapy (26% vs. 30%; relative risk, 0.86; 95% CI, 0.74 to 0.99; with 25 patients
needing to be treated on average to prevent one case of impairment). In post hoc analyses, we
found that this difference was almost entirely due to a reduction in profound impairment in the
aggressive-phototherapy group (9%, vs. 13% in the conservative-phototherapy group; relative
risk, 0.68; 95% CI, 0.52 to 0.89). As compared with the conservative-phototherapy group, the
aggressive-phototherapy group also had significant reductions in the rate of severe hearing
loss, in athetosis, and in Mental Developmental Index scores below 70 and below 85. However,
aggressive phototherapy did not significantly reduce rates of death or combined outcomes
including death or severe hearing loss, death or athetosis, or death or Mental Developmental
Index scores below 70. Adjustment for the presence or absence of bronchopulmonary dysplasia
had no material effect on the relative risks for the primary or secondary outcomes at 18 to 22
months.
Among the 1114 infants with a birth weight of 751 to 1000 g, aggressive phototherapy as
compared with conservative phototherapy was associated with a marginally significant
reduction in the rate of the primary outcome (relative risk, 0.87; 95% CI, 0.75 to 1.01) and
significant reductions in the rates of severe hearing loss and, in post hoc analyses, profound
neurodevelopmental impairment and the composite outcome of death or profound impairment
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at 18 to 22 months (Table 4). Other secondary outcomes listed were not significantly lower in
the aggressive-phototherapy group.
Among the 860 infants with a birth weight of 501 to 750 g, the relative risk of death or
neurodevelopmental impairment with aggressive phototherapy, as compared with conservative
phototherapy, was 1.00 (95% CI, 0.91 to 1.10). In this subgroup, there was an increase of 5
percentage points in the rate of death and a decrease of 5 percentage points in
neurodevelopmental impairment overall for aggressive phototherapy as compared with
conservative phototherapy; in a post hoc analysis, there was a reduction of 4 percentage points
in the rate of profound impairment (relative risk, 0.67; 95% CI, 0.46 to 0.98). The P value for
the interaction of treatment group and birth-weight category was 0.15. Results of Bayesian
analyses are shown in Figure 4 in the Supplementary Appendix; these analyses estimated an
89% probability that aggressive phototherapy increased the rate of death in this subgroup.
Relationship of Serum Bilirubin and Outcome
The mean (±SD) bilirubin level during the first 14 days among impaired survivors and
unimpaired survivors was 5.4±1.6 and 5.4±1.5 mg per deciliter (92±27 and 92±26 μmol per
liter), respectively (P = 0.45). Although the mean peak bilirubin level differed significantly
between impaired survivors and unimpaired survivors (8.6±2.3 vs. 8.3±2.3 mg per deciliter
[147±39 vs. 142±39 μmol per liter], P = 0.02), there was considerable overlap between the two
groups in the peak values (Fig. 5 in the Supplementary Appendix). The mean bilirubin level
among survivors with hearing loss as compared with those without hearing loss was 6.5±1.7
versus 5.4±1.5 mg per deciliter (111±29 vs. 92±26 μmol per liter) (range, 2.7 to 11.9 vs. 0.6
to 10.1 [46 to 203 vs. 10 to 173]), respectively (P<0.001). The mean peak bilirubin level among
survivors with hearing loss as compared with those without hearing loss was 10.5±2.3 vs. 8.4
±2.3 mg per deciliter (180±39 vs. 144±39 μmol per liter) (range, 5.8 to 17.8 vs. 1.3 to 17.7 [99
to 304 vs. 22 to 303), respectively (P<0.001).
Discussion
Decisions to use aggressive or conservative phototherapy in infants with extremely low birth
weights have been based on inferences from observational studies relating bilirubin level to
outcome.5-8,31 In this multicenter trial, we found no significant difference in the rate of death
or neurodevelopmental impairment (the primary outcome) at 18 to 22 months of corrected age
between neonates randomly assigned to receive aggressive phototherapy as compared with
those assigned to receive conservative phototherapy. However, aggressive phototherapy
significantly reduced the rate of neurodevelopmental impairment. In post hoc analyses, this
reduction was attributable almost entirely to there being fewer infants with profound
impairment in the aggressive-phototherapy group.
In prespecified subgroup analyses, the rate of death among infants weighing 501 to 750 g at
birth was higher, albeit not significantly so, with aggressive phototherapy than with
conservative phototherapy. In this subgroup, the absolute increase in the number of deaths
associated with aggressive phototherapy was 5 percentage points, a rate equal to the reduction
of 5 percentage points in overall neurodevelopmental impairment and a reduction of slightly
more than the 4 percentage points in profound impairment. The P value for the interaction
between treatment group and birth weight (P=0.15) was not significant, but the power of the
study was limited, and the possibility of an increase in the rate of death in the group with lower
birth weights, as supported by the Bayesian analysis,28,29,32,33 should be taken seriously.34
These findings are particularly worrisome because of the trend toward an increased rate of
death in the only previous major trial assessing phototherapy for neonatal hyperbilirubinemia.
14 In that trial, infants with a birth weight of less than 2500 g were randomly assigned to undergo
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either 96 hours of phototherapy or no phototherapy. The relative risk for death with
phototherapy was 1.49 (95% CI, 0.93 to 2.40) among the 77 infants of extremely low birth
weight and 1.32 (95% CI, 0.96 to 1.82) among the 1063 infants of low birth weight.17 Although
subgroup analyses must be viewed with skepticism, they are most likely to be valid when, as
in our study, they are supported by preexisting evidence, are preplanned, and are biologically
plausible.35,36
A reduction in the rate of death with conservative phototherapy might result from increased
antioxidant levels12 associated with higher bilirubin levels. Alternatively, a higher rate of death
with aggressive phototherapy might result from oxidative injury to cell membranes.37-39 Such
injury is particularly probable in the smallest, most immature infants whose gelatinous, thin
skin readily transmits light.40
The mechanism by which aggressive phototherapy would reduce the neurotoxic effects of
bilirubin probably involves a reduction in the level of unbound bilirubin. The overlap in
bilirubin values between infants with impairment and those without impairment and between
those with severe hearing loss and those without it provide little evidence to support a specific
bilirubin threshold causing impairment. Longer follow-up is needed to assess effects of
treatment on outcomes such as intelligence and executive function.
The reduced incidence of bronchopulmonary dysplasia in the aggressive-phototherapy group
was not hypothesized, could have been a result of chance, and did not appear to explain the
differences in outcome at 18 to 22 months. The number of days needed to regain birth weight
was almost identical in the two groups, suggesting that differences in fluid management are
unlikely to have caused a difference in the incidence of bronchopulmonary dysplasia.
The substantial reduction in overall neurodevelopmental impairment and profound impairment
that we observed occurred with a reduction of only 2.8 mg per deciliter (48 μmol per liter) in
mean peak bilirubin level during the first 14 days. Greater reductions in bilirubin might further
reduce impairment rates, providing the reductions could be safely achieved. Other treatment
strategies, including the use of tin mesoporphyrin,41 also warrant evaluation to identify the
safest and most effective strategies to address the postnatal rise in serum bilirubin level in
infants of extremely low birth weight.
In summary, we found no significant effect of aggressive phototherapy as compared with
conservative phototherapy on the primary outcome of death or neurodevelopmental
impairment in infants of extremely low birth weight, but the use of aggressive phototherapy
significantly reduced the overall rate of neurodevelopmental impairment. Aggressive
phototherapy may be preferred for infants with birth weights of 751 to 1000 g, because we
found significant neurodevelopmental benefits in this subgroup and no evidence that the
therapy increased the rate of death or other adverse outcomes at 18 to 22 months (including,
in post hoc analyses, the rate of profound impairment). For infants with a birth weight of 501
to 750 g, the possibility that increased mortality may offset any potential benefits of aggressive
phototherapy must be considered.
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Figure 1. Enrollment, Randomization, and Follow-up of the Study Patients
There were no significant differences at baseline between infants with known and those with
unknown neurodevelopmental status.
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Table 1
Baseline Characteristics of the Patients.*
Characteristic
Aggressive Phototherapy
(N = 990)
Conservative Phototherapy
(N = 984)
Birth weight — g 777±134 777±134
Gestational age — wk 26±2 26±2
Male sex — no. (%) 486 (49) 527 (54)
Race or ethnic group — no. (%)†
 Black 439 (44) 383 (39)
 Hispanic 174 (18) 190 (19)
 White 349 (35) 369 (38)
 Other 28 (3) 42 (4)
Antenatal corticosteroids — no./total no. (%) 783/986 (79) 783/978 (80)
Born in network center — no. (%) 906 (92) 881 (90)
Cesarean delivery — no./total no. (%) 656/990 (66) 627/981 (64)
5-Min Apgar score <5 — no./total no. (%) 136/980 (14) 128/974 (13)
Hematocrit at <12 hr of age — % 43.1±6.7 43.9±7.0
Positive result on Coombs test — no./total no. (%)
 Mother 28/680 (4) 31/664 (5)
 Infant 8/903 (1) 7/895 (1)
Maternal blood group O — no./total no. (%) 437/946 (46) 440/940 (47)
Maternal Rh positive — no./total no. (%) 825/946 (87) 826/940 (88)
Supplemental oxygen at 24 hr — no./ total no. (%) 647/987 (66) 642/983 (65)
Continuous positive airway pressure at 24 hr — no./
total no. (%)
209/988 (21) 191/983 (19)
Ventilation at 24 hr — no. (%)‡ 693/988 (70) 698/983 (71)
Baseline bilirubin in first 100 infants enrolled — mg/
dl
4.8±1.5 5.0±1.7
*
Plus–minus values are means ±SD. The denominator used to calculate the percentage of infants (or mothers) with a specific characteristic was the
number for whom the characteristic was known. This number was the total number in each group unless otherwise specified for percentages of patients
and except for hematocrit, for which data were available for 967 infants in the aggressive-phototherapy group and 954 in the conservative-phototherapy
group, and for baseline bilirubin, for which data were actually obtained for 101 and 102 infants, respectively. Significant differences were found
between the two groups for male sex (P = 0.047), race or ethnic group (P = 0.049), and hematocrit at less than 12 hours of age (P = 0.006). To convert
the values for bilirubin to micromoles per liter, multiply by 17.1.
†
Race or ethnic group was reported by parents or guardians of the patients or was determined by the physician on chart review.
‡
Ventilation was defined as high-frequency, intermittent mechanical ventilation or nasal synchronized intermittent mechanical ventilation.
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Table 2
Findings in Study Patients before or at Discharge.*
Variable or Outcome Aggressive Phototherapy Conservative Phototherapy P Value
Variable
Total serum bilirubin at start
of phototherapy — mg/dl
4.8±1.6 10.0±1.5 <0.001
Daily total serum bilirubin,
day 1–14 — mg/dl
4.7±1.1 6.2±1.5 <0.001
Peak total serum bilirubin,
day 1–14 — mg/dl
7.0±1.8 9.8±2.1 <0.001
Age at peak bilirubin — hr 95±69 75±45 <0.001
Unbound bilirubin at day 5
— mg/dl
0.33±0.25 0.48±0.33 <0.001
Age when phototherapy
started — hr
23±9 58±26 <0.001
Duration of phototherapy —
hr
88±48 35±31 <0.001
Exchange transfusions —
no.†
2 3 0.69
Days to regain birth weight 12.6±6.2 12.5±6.6 0.65
Length of hospital stay
among survivors — days
97±43 100±47 0.11
Relative Risk
(95% CI)‡
Predischarge secondary
outcome — no./total no.
(%)
Death before day 15 96/990 (10) 95/984 (10) 1.00 (0.78–1.30)
Death before discharge 209/990 (21) 201/984 (20) 1.03 (0.88–1.21)
Intraventricular hemorrhage,
grade 3 or 4
210/969 (22) 224/955 (23) 0.93 (0.79–1.10)
Death or intraventricular
hemorrhage, grade 3 or 4
291/984 (30) 290/976 (30) 1.0 (0.88–1.14)
Patent ductus arteriosus 459/990 (46) 487/984 (49) 0.93 (0.86–1.02)
Death or patent ductus
arteriosus
556/990 (56) 582/984 (59) 0.95 (0.88–1.02)
Necrotizing enterocolitis 105/990 (11) 117/984 (12) 0.90 (0.70–1.14)
Death or necrotizing
enterocolitis
269/990 (27) 268/984 (27) 1.00 (0.87–1.15)
Bronchopulmonary
dysplasia at 36 wk
postmenstrual age
327/799 (41) 383/797 (48) 0.86 (0.78–0.96)
Death or bronchopulmonary
dysplasia at 36 wk post-
menstrual age
506/978 (52) 559/973 (57) 0.90 (0.84–0.97)
Retinopathy of prematurity
≥stage 3§
153/802 (19) 160/798 (20) 0.98 (0.81–1.18)
Death or retinopathy of
prematurity ≥stage 3
354/967 (37) 355/955 (37) 0.99 (0.89–1.10)
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Variable or Outcome Aggressive Phototherapy Conservative Phototherapy P Value
Late-onset sepsis 387/946 (41) 414/942 (44) 0.93 (0.84–1.04)
Death or late-onset sepsis 502/990 (51) 519/984 (53) 0.96 (0.89–1.04)
*
Plus–minus values are means ±SD. The denominator used to calculate the percentage of infants with a specific outcome was the number of infants
randomly assigned to each treatment group for whom that outcome was known at the time of hospital discharge, unless otherwise noted. These numbers
of infants in the aggressive-phototherapy group and the conservative-phototherapy group were as follows: 781 and 755 for total serum bilirubin; 990
and 982 for daily total serum bilirubin, peak total serum bilirubin, and age at peak bilirubin; 498 and 511 for unbound bilirubin; 981 and 757 for age
when phototherapy started (215 patients assigned to conservative phototherapy never received phototherapy); 923 and 954 for duration of phototherapy;
990 and 984 for exchange transfusions; 832 and 841 for days to regain birth weight; and 778 and 782 for length of hospital stay among survivors. To
convert the values for bilirubin to micromoles per liter, multiply by 17.1.
†
The P value for the number of exchange transfusions was calculated with the use of Fisher's exact test, without adjustment for birth-weight stratum
or center.
‡
The relative risk of each outcome was calculated for aggressive phototherapy as compared with conservative phototherapy. The P values were not
significant except for bronchopulmonary dysplasia at 36 weeks of postmenstrual age and death or bronchopulmonary dysplasia at 36 weeks of
postmenstrual age, for which the P value was less than 0.05.
§
Retinopathy of prematurity was defined according to criteria of the International Committee for Classification of Retinopathy of Prematurity.
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Table 3
Primary and Other Outcomes at 18 to 22 Months.*
Outcome Aggressive Phototherapy Conservative Phototherapy
Relative Risk
(95% CI)†
no./total no. (%)
Death or neurodevelopmental
impairment
465/902 (52) 493/902 (55) 0.94 (0.87–1.02)
Death‡ 230/946 (24) 218/944 (23) 1.05 (0.90–1.22)
Neurodevelopmental impairment 235/902 (26) 275/902 (30) 0.86 (0.74–0.99)§
Profound impairment¶ 80/895 (9) 119/896 (13) 0.68 (0.52–0.89)§
Death or profound impairment 310/895 (35) 337/896 (38) 0.92 (0.82–1.03)
Cerebral palsy|
 Mild, moderate, or severe 81/929 (9) 91/924 (10) 0.89 (0.67–1.18)
 Moderate or severe 38/929 (4) 53/923 (6) 0.71 (0.47–1.07)
Death or cerebral palsy
 Mild, moderate, or severe 311/929 (34) 309/924 (33) 1.00 (0.89–1.13)
 Moderate or severe 268/929 (29) 271/923 (29) 0.99 (0.86–1.13)
Severe hearing loss| 9/925 (1) 28/922 (3) 0.32 (0.15–0.68)§
Death or severe hearing loss 239/925 (26) 246/922 (27) 0.97 (0.84–1.12)
Blindness| 2/928 (<1) 7/924 (1) 0.28 (0.06–1.37)
Death or blindness 232/928 (25) 225/924 (24) 1.03 (0.88–1.19)
Mental Developmental Index
score <70
194/905 (21) 234/904 (26) 0.83 (0.71–0.98)§
Death or Mental Developmental
Index score <70
424/905 (47) 452/904 (50) 0.94 (0.86–1.02)
Psychomotor Developmental
Index score <70
127/898 (14) 152/894 (17) 0.84 (0.68–1.04)
Death or Psychomotor
Developmental Index score <70
357/898 (40) 370/894 (41) 0.96 (0.86–1.06)
Mental Developmental Index
score <85
380/905 (42) 429/904 (47) 0.89 (0.80–0.98)§
Death or Mental Developmental
Index score <85
610/905 (67) 647/904 (72) 0.94 (0.89–1.00)§
Psychomotor Developmental
Index score <85
262/898 (29) 299/894 (33) 0.88 (0.77–1.01)
Death or Psychomotor
Developmental Index score <85
492/898 (55) 517/894 (58) 0.95 (0.88–1.03)
Athetosis| 2/929 (<1) 10/923 (1) 0.20 (0.04–0.90)§
Death or athetosis 232/929 (25) 228/923 (25) 1.01 (0.87–1.17)
Seizures| 29/933 (3) 28/925 (3) 1.03 (0.62–1.71)
Normal gross motor function 556/929 (60) 545/923 (59) 1.01 (0.94–1.08)
Ability to walk fluently** 544/929 (59) 529/924 (57) 1.02 (0.95–1.10)
Fine pincer grasp 606/929 (65) 582/922 (63) 1.03 (0.97–1.10)
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Outcome Aggressive Phototherapy Conservative Phototherapy
Relative Risk
(95% CI)†
no./total no. (%)
Weight below 5th percentile for
age
242/929 (26) 255/924 (28) 0.94 (0.81–1.10)
Fronto-occipital circumference
below 5th percentile for age
120/929 (13) 128/922 (14) 0.93 (0.74–1.17)
*
The denominator used to calculate the percentage of infants with a specific outcome was the number of infants randomly assigned to each treatment
group for whom that outcome was known at 18 to 22 months. The Mental and Psychomotor Developmental Indexes are from the Bayley Scales of
Infant Development II (on which scores can range from 50 to 150, with 150 indicating the most advanced development).
†
The relative risk of each outcome was calculated for aggressive phototherapy as compared with conservative phototherapy.
‡
The mean (±SD) age at death was 57±98 days (range, 1 to 673) in the aggressive-phototherapy group and 52±88 days (range, 0 to 622) in the
conservative-phototherapy group. The causes of death and the Kaplan–Meier survival estimates are shown in Table 1 and Figure 2 in the Supplementary
Appendix.
§
P<0.05.
¶
Infants with profound impairment included 22 with a Mental Developmental Index score of 50 and 121 with a score of less than 50.
|
Center was removed from the model owing to the absence of this rare outcome at several centers.
**
The ability to walk fluently was defined as the ability to take 10 steps, unassisted, with a normal gait for the age.
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Table 4
Secondary Analyses, According to Birth-Weight Stratum.*
Outcome Aggressive Phototherapy Conservative Phototherapy
Relative Risk
(95% CI)†
no./total no. (%)
Death or neurodevelopmental
impairment
 501–750 g 272/405 (67) 270/403 (67) 1.00 (0.91–1.10)
 751-1000 g 193/497 (39) 223/499 (45) 0.87 (0.75–1.01)
Death‡
 501–750 g 163/417 (39) 142/412 (34) 1.13 (0.96–1.34)
 751–1000 g 67/529 (13) 76/532 (14) 0.90 (0.66–1.21)
Neurodevelopmental impairment
 501–750 g 109/405 (27) 128/403 (32) 0.86 (0.70–1.05)
 751–1000 g 126/497 (25) 147/499 (29) 0.86 (0.71–1.05)
Death or profound impairment
 501–750 g 202/403 (50) 200/400 (50) 1.00 (0.88–1.14)
 751–1000 g 108/492 (22) 137/496 (28) 0.79 (0.64–0.99)§
Profound impairment¶
 501–750 g 39/403 (10) 58/400 (14) 0.67 (0.46–0.98)§
 751–1000 g 41/492 (8) 61/496 (12) 0.68 (0.47–0.99)§
Death or moderate or severe
cerebral palsy
 501–750 g 181/410 (44) 169/408 (41) 1.06 (0.91–1.24)
 751–1000 g 87/519 (17) 102/515 (20) 0.86 (0.66–1.11)
Moderate or severe cerebral
palsy¶
 501–750 g 18/410 (4) 27/408 (7) 0.66 (0.37–1.19)
 751–1000 g 20/519 (4) 26/515 (5) 0.76 (0.43–1.35)
Death or severe hearing loss
 501–750 g 167/408 (41) 152/407 (37) 1.09 (0.93–1.28)
 751–1000 g 72/517 (14) 94/515 (18) 0.77 (0.58–1.02)
Severe hearing loss¶
 501–750 g 4/408 (1) 10/407 (2) 0.40 (0.13–1.26)
 751–1000 g 5/517 (1) 18/515 (3) 0.28 (0.10–0.74)§
Death or Mental Development
Index score <70
 501–750 g 251/405 (62) 253/402 (63) 0.98 (0.89–1.09)
 751–1000 g 173/500 (35) 199/502 (40) 0.88 (0.75–1.03)
Mental Developmental Index
score <70
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Outcome Aggressive Phototherapy Conservative Phototherapy
Relative Risk
(95% CI)†
no./total no. (%)
 501–750 g 88/405 (22) 111/402 (28) 0.80 (0.63–1.01)
 751–1000 g 106/500 (21) 123/502 (25) 0.87 (0.69–1.08)
Death or Psychomotor
Developmental Index score <70
 501–750 g 227/404 (56) 218/399 (55) 1.03 (0.91–1.16)
 751–1000 g 130/494 (26) 152/495 (31) 0.86 (0.71–1.05)
Psychomotor Developmental
Index score <70¶
 501–750 g 64/404 (16) 76/399 (19) 0.83 (0.61–1.13)
 751–1000 g 63/494 (13) 76/495 (15) 0.84 (0.62–1.14)
Death or Mental Developmental
Index score <85
 501–750 g 315/405 (78) 326/402 (81) 0.96 (0.89–1.03)
 751–1000 g 295/500 (59) 321/502 (64) 0.92 (0.84–1.02)
Mental Developmental Index
score <85
 501–750 g 152/405 (38) 184/402 (46) 0.83 (0.71–0.98)§
 751–1000 g 228/500 (46) 245/502 (49) 0.93 (0.82–1.06)
Psychomotor Developmental
Index score <85
 501–750 g 117/404 (29) 130/399 (33) 0.91 (0.75–1.10)
 751–1000 g 145/494 (29) 169/495 (34) 0.87 (0.73–1.03)
Athetosis¶
 501–750 g 1/410 (<1) 5/407 (1) 0.20 (0.02–1.69)
 751–1000 g 1/519 (<1) 5/516 (1) 0.20 (0.02–1.70)
*
The denominator used to calculate the percentage of infants with a specific outcome was the number of infants randomly assigned to each treatment
group, and classified in each birth-weight subgroup, for whom that outcome was known at 18 to 22 months. The Mental and Psychomotor
Developmental Indexes are from the Bayley Scales of Infant Development II (on which scores can range from 50 to 150, with 150 indicating the most
advanced development).
†
The relative risk of each outcome was calculated for aggressive phototherapy as compared with conservative phototherapy.
‡
Among infants whose birth weight was 650 g or less, 106 of 214 (50%) died in the aggressive-phototherapy group, as compared with 80 of 212
(38%) in the conservative-phototherapy group (P = 0.03).
§
P<0.05.
¶
Center was removed from the model owing to the absence of this rare outcome at several centers.
N Engl J Med. Author manuscript; available in PMC 2010 February 12.
